AARS1 Gene Early Infantile Epileptic Encephalopathy Type 29 NGS Genetic DNA Test
Introduction
The AARS1 Gene Early Infantile Epileptic Encephalopathy Type 29 NGS Genetic DNA Test is a specialized diagnostic tool designed to identify genetic mutations associated with severe neurological disorders in infants. This test is crucial for early diagnosis and intervention, allowing for tailored treatment plans that can significantly improve outcomes for affected children.
What the Test Measures
This test specifically detects mutations in the AARS1 gene, which are linked to early infantile epileptic encephalopathy (EIEE). By employing Next Generation Sequencing (NGS) technology, the test provides a comprehensive analysis of the genetic material, revealing potential anomalies that may contribute to the onset of seizures and other neurological symptoms.
Who Should Consider This Test
Parents should consider the AARS1 Gene test if their infant exhibits:
- Severe and unexplained seizures
- Developmental delays
- Abnormal muscle tone or movement
- Family history of epilepsy or neurological disorders
Benefits of Taking the Test
- Early diagnosis of genetic causes of epilepsy
- Informed treatment decisions based on genetic findings
- Access to genetic counseling for families
- Potential eligibility for targeted therapies
Understanding Your Results
Results from the AARS1 Gene test can provide critical insights into the underlying genetic factors contributing to your child’s condition. A genetic counselor will assist in interpreting the results and discussing the implications for treatment and family planning.
Test Pricing
| Price Type | Amount (NGN) |
|---|---|
| Discount Price | 400,000 NGN |
| Regular Price | 560,000 NGN |
Book the Test
To ensure your child receives the best care possible, book the AARS1 Gene Early Infantile Epileptic Encephalopathy Type 29 NGS Genetic DNA Test today. For more information or to schedule an appointment, please call or WhatsApp us at +2348077798758.
